Clinical Efficacy of Mosapride on Functional Dyspepsia Patients Overlapping Constipation-predominant Irritable Bowel Syndrome

Objective To explore the clinical efficacy of mosapride on functional dyspepsia patients overlapping constipation-predominant irritable bowel syndrome.Methods 60 functional dyspepsia(FD) patients overlapping constipation-predominant irritable bowel syndrome were randomly given mosapride(5 mg,tid) or trimebutine maleate(0.1 mg,tid) for 4 weeks.The clinical efficacy was analyzed at the end of clinical course and 2 weeks later.Results At the end of 4-week trails,the symptoms associated to FD,such as postprandial fullness,early satiety,and upper abdominal pain,in patients treated with mosapride were more sufficiently improved compared to those in patients treated with trimebutine maleate(P0.05).However,no significant difference as to symptoms above-mentioned was found between 2 therapies 2 weeks later(P0.05).Additionally,similar unobvious differences between 2 therapies were also detected both at the end of clinical trials and 2 weeks later regarding to the symptoms including bloating,stool property and stool frequency(P0.05).Conclusion These findings suggest that mosapride is safe and sufficient for treating the unctional dyspepsia patients overlapping constipation-predominant irritable bowel syndrome.